ESBA105, an anti-TNF alpha antibody fragment designed to reduce inflammation in patients undergoing cataract surgery, has begun a Phase Ib/IIa trial, according to an announcement from ESBATech AG, the antibody's developer.
ESBA105, an anti-TNF alpha antibody fragment designed to reduce inflammation in patients undergoing cataract surgery, has begun a Phase Ib/IIa trial, according to an announcement from ESBATech AG, the antibody's developer.
The randomized, double-blind, placebo-controlled study will assess the safety, tolerability, ocular pharmacokinetics and efficacy of postoperative inflammation inhibition of ESBA105, when applied topically to patients undergoing cataract surgery.
The Phase I trial of ESBA105, which was concluded in August 2008, demonstrated that ESBA105 was able to penetrate both the anterior and the posterior of the eye effectively, and to be present in significant levels in the vitreous. The primary investigator in the Phase Ib/IIa study is Michael A. Thiel, MD, PhD, head of the department of ophthalmology at the Kantonsspital, Lucerne, Switzerland.
AAO 2024: Detail outlined for Artificial Intelligence Innovation Center at Wilmer Eye Institute
October 24th 2024During a conversation at the American Academy of Ophthalmology annual meeting in Chicago, T.Y. Alvin Liu, MD, discussed plans for the James P. Gills Jr, MD, & Heather Gills Artificial Intelligence Innovation Center at the Wilmer Eye Institute at Johns Hopkins Medicine.
AAO 2024: Transient vision loss with Alexander Fein, MD
October 21st 2024Alexander Fein, MD, spoke with the Eye Care Network to share how to approach a patient presenting with transient vision loss, what this type of vision loss can mean, and what additional testing might be needed to determine the best plan for care.